| Name | Title | Contact Details |
|---|
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc